Risk of tumorigenicity in mesenchymal stromal cell–based therapies—Bridging scientific observations and regulatory viewpoints
Top Cited Papers
- 1 July 2013
- journal article
- review article
- Published by Elsevier BV in Cytotherapy
- Vol. 15 (7), 753-759
- https://doi.org/10.1016/j.jcyt.2013.03.005
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Spectrum of Cancer Risk Among US Solid Organ Transplant RecipientsJAMA, 2011
- Large-Scale Analysis Reveals Acquisition of Lineage-Specific Chromosomal Aberrations in Human Adult Stem CellsCell Stem Cell, 2011
- Isolation of mouse mesenchymal stem cells with normal ploidy from bone marrows by reducing oxidative stress in combination with extracellular matrixBMC Cell Biology, 2011
- Spontaneous Malignant Transformation of Human Mesenchymal Stem Cells Reflects Cross-Contamination: Putting the Research Field on Track – LetterCancer Research, 2010
- Low physiologic oxygen tensions reduce proliferation and differentiation of human multipotent mesenchymal stromal cellsBMC Cell Biology, 2010
- Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2The Journal of Pathology, 2009
- Catch of the day: zebrafish as a human cancer modelOncogene, 2008
- DNA damage-induced cell death by apoptosisTrends in Molecular Medicine, 2006
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006
- Incidence of cancer after kidney transplant: results from the North Italy transplant programTransplantation, 2003